Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2025 · 10-Q
Revenue$47.63M$47.63M+14.7% vs Q2 2024 Net Income$4.85M$4.85MN/M vs Q2 2024 EPS Diluted$0.24$0.24N/M vs Q2 2024 Operating Income$8,444,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$15,585,000+20.8% Margins · derivedOperating margin17.7%+63.7 pt vs Q2 2024
Net margin10.2%+135.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 8, 2025 · 39 d after period end